CompletedNot Applicable

Magnesium Supplementation in Simultaneous Pancreas-Kidney Transplantation

United Kingdom40 participantsStarted 2008-01-02

Plain-language summary

Magnesium is essential in human physiology. Simultaneous pancreas-kidney (SPK) transplant recipients frequently experience hypomagnesemia. The effects of hypomagnesaemia are harmful. This observational study assessed intraoperative magnesium supplementation's utility in patients undergoing SPK transplantation. Perioperative hemodynamics were monitored. Postoperative serum magnesium was monitored at 12 hours and 48 hours.

Who can participate

Age range20 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult diabetic patients who require insulin therapy and hemodialysis due to pancreatic-kidney failure. Exclusion Criteria: * Adult diabetic patients who do not require insulin therapy and hemodialysis.

What they're measuring

Serum magnesium levels.

Timeframe: 48 hours

Perioperative cardiovascular incidents.

Timeframe: 48 hours

Trial details

NCT IDNCT06766786

SponsorDr Olu Bamgbade, MD, FRCPC

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-02-20

View on ClinicalTrials.gov More Renal Failure Chronic Requiring Dialysis trials